Cover Image
市場調查報告書

經由鼻子服用藥物的美國市場

Intranasal Drug Delivery

出版商 Global Industry Analysts, Inc. 商品編碼 243057
出版日期 內容資訊 英文 212 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
經由鼻子服用藥物的美國市場 Intranasal Drug Delivery
出版日期: 2016年05月01日 內容資訊: 英文 212 Pages
簡介

本報告書內容包括:經由鼻子服用的藥物之美國市場的各治療領域的分析、2009-2017年間的每年業績推算/預測和6年間的歷史性分析、及主要/利基玩家71家的企業介紹、內容綱要摘記如下:

第1章 介紹、方法論、產品定義

第2章 美國市場報告書

第3章 業界概要

  • 藥物傳輸:入門
  • 鼻:透過血液腦關門的魅力路徑
  • 藥物自我給藥為經由鼻子服用藥物為焦點
  • 經由鼻子服用藥物的新治療領域的開拓研究和技術
  • R&D:經由鼻子服用藥物的商業化不可欠缺
  • 經由鼻子服用的藥物為所有的藥物傳輸研究專案的主題之理由
  • 經由鼻子服用的藥物機器/設備
  • 防腐劑無添加系統 (PFS)
  • 傳統的 vs. 先進の經由鼻子服用的藥物設備
  • 雙方向經由鼻子服用的藥物:很大的可能性之技術
  • 依據研究調查所證明的雙方向傳輸的優點
  • 美國的鼻腔噴劑設備的市場
  • Flonase的專利失效後GSK的佔有率被Merck剝奪

第4章 市場動態

  • 藥物傳輸的創新:成功的保衛
  • 控制放出技術為話題的言語
  • 標的特異性給藥設備:重大的價值
  • 安全性和成本:第一的成長牽引力
  • 鼻腔噴霧製劑的防腐劑衰退
  • 對微生物汚染的抵抗力所提供的多量投藥容器的進化
  • 生物學的使用率:經由鼻子服用的藥物的重要一面
  • 化學的改質
  • 過渡的改質和限制的酵素活性
  • 大型分子的生物學使用率
  • 生體附著性聚合物:有益於藥劑吸收性的增大
  • 降血鈣素經鼻噴霧的有效性之各種意見
  • 咳嗽/過敏部門的架構之點鼻劑
  • 影響市場機會的專利失效

第5章 技術的概要

  • 經由鼻子服用的藥物:記述的解說
  • 鼻子的生理學
  • 鼻藥劑的製劑之課題
  • 經鼻藥:處方藥 (Rx) 和市場銷售藥 (OTC)
  • 全身性給藥和局部效果的差異
  • 點鼻粉末劑 vs. 噴霧劑
  • 經由鼻子服用藥物設備
  • 藥物傳輸設備的種類
  • 其他給藥技術的經由鼻子服用藥物
  • 經由鼻子服用藥物的限制
  • 過敏
  • 定義
  • 症狀
  • 過敏性鼻炎
  • 鼻子過敏

第6章 鼻藥劑:概要

  • 過敏用鼻藥劑
  • 停經後骨質疏鬆症專用經鼻藥劑
  • 經鼻疼痛管理藥
  • 經鼻疫苗接種
  • 性功能不健全專用經鼻藥劑
  • 戒菸支援用鼻腔噴霧劑
  • 生產線中的經鼻藥劑

第7章 主要研究開發策略

第8章 最近的技術性發展

第9章 產品介紹/創新

第10章 產品創新/介紹:歷史的展望材料

第11章 最近的業界活動

第12章 企業活動:歷史的展望材料

第13章 全球的主要玩家為焦點

第14章 市場分析

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: MCP-1795

This report analyzes the US market for Intranasal Drug Delivery in US$ Million by the following Therapeutic Areas: Allergic Infections, Analgesics, Osteoporosis, and Vaccinations. Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for this market. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 59 companies including many key and niche players such as -

Aegis Therapeutics LLC
AptarGroup, Inc.
AstraZeneca Plc
Becton Dickinson and Company
GlaxoSmithKline Plc

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

  • Study Reliability and Reporting Limitations
  • Disclaimers
  • Data Interpretation & Reporting Level
    • Quantitative Techniques & Analytics
  • Product Definitions and Scope of Study

II. A US MARKET REPORT

1. INDUSTRY OVERVIEW

  • Drug Delivery: A Quick Primer
  • The Nose: An Attractive Avenue to Cross the Blood Brain Barrier
  • Self-Administration of Drugs Brings Intranasal Drug Delivery Into the Spotlight
  • Research & Technology Opens Up New Therapeutic Areas for Nasal Drug Delivery
    • Product Developments in the US Intranasal Drug Delivery Market
  • R&D: Critical to the Commercialization of Intranasal Drug Delivery
    • Tight Junction Biology: A Key Speed Breaker in Commercialization
    • RNA Interference (RNAi): A Tool to Manipulate Tight Junctions
  • Why Is Nasal Drug Delivery the Theme of All Drug Delivery Research Projects?
  • Nasal Drug Delivery Devices & Equipment
  • Preservative Free Systems (PFS)
  • Traditional Vs. Advanced Intranasal Drug Delivery Devices
  • Bi-Directional Nasal Drug Delivery: A Technology With a Huge Potential
  • Benefits of Bi-Directional Delivery Authenticated Through Research Studies
  • Market for Nasal Spray Devices in the US
  • GSK Looses Share to Merck, Following Patent Expiry of Flonase
    • Table 1: US Intra-Nasal Steroid Market for Allergic Rhinitis: Sales of Leading Nasal Formulations for 2008 (includes corresponding Graph/Chart)
    • Table 2: The US Nasal Drug Delivery Market for Allergic Rhinitis: Sales Of Top Four Nasal Steroid Formulations for The Year 2005 (In US$ Million) (includes corresponding Graph/Chart)

2. MARKET DYNAMICS

  • Innovation in Drug Delivery: A Talisman For Success
  • Controlled Release Technology Is the Buzz Word
  • Target-Specific Delivery Devices: Of Critical Value
  • Safety and Cost: Primary Growth Drivers
  • Preservatives Losing Sheen in Nasal Spray Formulations
  • Multi-Dose Containers Evolve to Offer Resistance Against Microbial Contamination
  • Bioavailability: An Important Facet of Intranasal Drug Delivery
  • Chemical Modification
  • Transient Modification & Limited Enzymatic Activity
  • Bioavailability of Large Molecules
  • Bio-Adhesive Polymers: Useful in Increasing Drug Absorption
  • Mixed Opinions on Efficiency of Calcitonin Nasal Spray
  • Nasal Preparations Gaining Foothold in Cough and Allergic Categories
  • Patent Expiries Impact Market Opportunities

3. TECHNOLOGY OVERVIEW

  • Intranasal Drug Delivery: A Descriptive Exposition
  • Nasal Physiology
  • Challenges Involved In Formulating Nasal Drugs
    • The Importance of Bioadhesion
    • Overview of the Traditional Drug Administration Routes, Molecular Weight Capabilities, and Dosage Range
  • Intranasal Drugs - Prescription (Rx) and Over-the- Counter (OTC)
  • Differences Between Systemic Delivery and Local Effects
  • Nasal Powders Vs. Sprays
  • Nasal Drug Delivery Devices
  • Types of Drug Delivery Devices
    • Droppers
    • Sprays
    • Aerosol Containers/Inhalers
    • Pumps
    • Nasal Aspirator
  • Intranasal Drug Delivery Vis-a-vis Other Delivery Techniques
    • Table 3: US Market for Intranasal Drugs: Percentage share of Topical and Systemic Drugs by value for the Years 2006 and 2015 (includes corresponding Graph/Chart)
  • Limitations of Intranasal Drug Delivery
  • Allergy
  • Definition
  • Symptoms
  • Allergic Rhinitis
  • Nasal Allergies
    • Table 4: US Market for Nasal Sprays: Top Five Nasal Sprays for Cough, Cold, Sinus and Allergy Ranked by Dollar Retail Sales for the Year Ended January 2008 (In US $ Million) (includes corresponding Graph/Chart)
    • Table 5: US Market for Nasal Sprays, Drops and Inhalers: Top 10 Brands Ranked by Dollar Sales through Drug Stores for the Year Ended January 2008 (In US $ Million) (includes corresponding Graph/Chart)
    • Table 6: US Market for Nasal Sprays, Drops and Inhalers: Top 10 Brands Ranked by Unit Sales through Drug Stores for the Year Ended January 2008 (In Thousand Units) (includes corresponding Graph/Chart)

4. NASAL DRUGS: AN OVERVIEW

  • Nasal Drugs for Allergies
  • Corticosteroid Nasal Sprays
    • Flonase
    • Patanase
    • Beconase
    • Other Nasal Corticosteroid Drugs
  • Antihistamine Nasal Sprays
    • Astelin Nasal Spray
    • Otrivin Nasal Spray
    • Livostin Nasal Spray
    • Other Nasal Antihistamine Drugs
      • Select Brands of Allergy Relievers
  • Nasal Drugs for Postmenopausal Osteoporosis
  • Calcitonin-Salmon Nasal Spray
  • Miacalcin Nasal Spray
  • Fortical(r) Nasal Spray
  • Intranasal Pain Management Drugs
  • Stadol Nasal Spray
  • Imitrex
  • Migranal
  • Zolmitriptan Nasal Spray
    • Intranasal Analgesics for Treating Migraine
  • Intranasal Vaccination
  • Process of Intranasal Immunization
  • Market Drivers
  • "LAIV" Nasal Spray Flu Vaccine
  • FluMist(r) Vaccine From MedImmune
  • Intranasal Drugs for Sexual Dysfunction
  • Nasal Spray for Treating Vitamin B12 Deficiency
  • Nasal Spray for Aiding Smoking Cessation
  • Intranasal Drugs in Pipeline

5. SELECT RESEARCH & DEVELOPMENT INITIATIVES

  • Nastech Enrolls 551 Patients for Phase 2 Trials of PYY3-36 Nasal Spray
  • Archimedes Pharma Commences Phase III Trials for NasalFent(r)
  • Archimedes Presents New Clinical Data on NasalFent(r)
  • LigoCyte Commences Clinical Trials for Intranasal Norovirus Vaccine
  • Javelin Pharmaceuticals Reveals Phase 2 Study Results for PMI-100/150
  • Javelin Pharmaceuticals Commences Phase III studies for PMI-150
  • Nastech Commences Phase 2 Trials for Insulin Nasal Spray
  • ACAAI Reveals Results for Trials of Nasacort(r) AQ Nasal Spray in Children
  • TGAR01H from Fabre Kramer
  • Aegis Therapeutics Completes First Human Clinical Study on Intravail(r)
  • Nastech Pharmaceutical Presents Clinical Test Results on Parathyroid Hormone
  • Zolmitriptan Promises Relief for Cluster Headaches
  • CAIV-T: More Effective than Injectable Influenza Vaccines
  • Intranasal Therapeutics Conducts Study on Midazolam
  • Nastech Announces Phase I Results of Insulin Nasal Spray
  • Archimedes Completes Phase II Trials of NASALFENT
  • Intranasal Corticosteroid Proven Effective for Treating Allergic Rhinitis
  • Aegis Files DMF for Intravail
  • Nasal Sprays: A New-Generation Treatment for Gynecological Problems
  • Aegis Therapeutics Conducts Feasibility Study on Drug Delivery Technology
  • GelVac Powder Delivery System Completes Phase I Clinical Trial
  • OptiNose Develops Intranasal Delivery System for Osteoporosis
  • Nastech Initiates Dose Ranging Study of PYY(3-36)
  • Valois Develops New Nasal Dispensing System
  • Rigel Pharmaceuticals to Initiate R112 Phase II Clinical Trial
  • MedPointe Pharmaceuticals Demonstrates ACT1 Study Results on ASTELIN(r)
  • Bentley Pharmaceuticals Demonstrates Clinical Trial Results of its Intra Nasal Insulin Spray

6. RECENT TECHNOLOGICAL DEVELOPMENTS

  • New-Generation Technologies and Devices
  • ViaNase from Kurve Technology
  • A New Product from OptiNose
  • Nastech's "Tight Junction Biology" Research Program
  • ChiSys(tm) Nasal Delivery Technology from Archimedes

7. PRODUCT INTRODUCTIONS/INNOVATIONS

  • TheraBiogen to Introduce TheraMax Cold & Flu Nasal Spray
  • Sinus Dynamics(tm) Unveils NasaTouch(tm) Nasal Delivery Device
  • 3M Drug Delivery Systems Introduces Nasal MDI
  • MeadWestvaco Introduces Preservative-Free Nasal Pumps
  • GlaxoSmithKline Introduces Avamys Nasal Spray

8. PRODUCT INNOVATIONS/INTRODUCTIONS - A HISTORIC PERSPECTIVE BUILDER

  • Aegis Therapeutics Develops ProTek(tm)
  • Heel Launches Luffeel(r) in the US
  • Archimedes to Introduce Intranasal Formulation of Human Growth Hormone
  • Sinofresh Launches SinoFresh(tm) Nasal & Sinus Care
  • PARI Respiratory Launches Nasal Drug Delivery Program
  • OptiNose to Develop New Range of Intranasal Products
  • OptiNose and Cambridge Consultants to Develop Advanced Nasal Delivery Device
  • Kurve Technology Develops ViaNase ID(tm)
  • Upsher-Smith Introduces Fortical(r) Nasal Spray
  • Schering-Plough Launches New Formulation of NASONEX(r)

9. RECENT INDUSTRY ACTIVITY

  • Marina Biotech Obtains Patent Rights for Intranasal Insulin Delivery in China
  • Takeda Acquires Nycomed
  • Upsher-Smith Acquires ITI-111 from Ikano Therapeutics
  • Hospira Acquires Javelin Pharmaceuticals
  • Archimedes Pharma Receives Approval for PecFent Nasal Spray
  • Cypress Bioscience Obtains Patent Rights for Carbetocin Therapy
  • MDRNA, Inc. Announces Change of Name
  • Prosonix Inks Product Co-Development and Licensing with Trimel Biopharma
  • Serenity Pharmaceuticals and Allergan Sign Agreement
  • Ethicon Acquires Acclarent
  • Ikano's Midazolam Obtains Orphan Drug Designation
  • FDA Issues Not-Approvable Letter for Nastech's Generic Calcitonin-Salmon
  • Trimel BioPharma Acquires Direct Haler
  • Lupin Takes Over AllerNaze(tm) Rights from Collegium Pharmaceutical
  • Nanotherapeutics Purchases DelSite Assets
  • Schering-Plough Merges with Merck
  • Valois Pharma and Nycomed Launch Spray Pump for Fentanyl
  • Phylogica and Aegis Therapeutics Collaborate
  • Intranasal Therapeutics is Now Ikano Therapeutics

10. CORPORATE ACTIVITY - A HISTORIC PERSPECTIVE BUILDER

  • FDA Clears Use of New Clone in Calcitonin Production of Unigene
  • Zelos Therapeutics Collaborates with Aegis Therapeutics
  • ImmuneRegen BioSciences Partners with LRRI
  • Avamys(tm) Nasal Spray Receives Approval in Europe
  • PMI-150 Receives Canadian Patent
  • Javelin Releases Phase III Data of Rylomine Intranasal Morphine
  • FDA Recommends Supplemental Study for Javelin's PMI-150
  • Palatin Re-Acquires Bremelanotide Rights from King Pharma
  • USFDA Approves FluMist(r) for Young Children
  • USFDA Approves Veramyst Nasal Spray for Individuals Aged Two Years and Above
  • Kurve Technology Inks Agreement with Schering-Plough
  • MedImmune Clarifies FDA Observations
  • FluMist(R) Receives FDA Approval for Refrigerated Formulation
  • Nastech Regains Rights for PTH1-34 Nasal Spray
  • NASONEX(R) Receives Ease-of-Use Commendation from Arthritis Foundation
  • Aegis Therapeutics Establishes Cedar Therapeutics Inc.
  • EMEA Provides Encouraging Feedback for Avamys(tm) Nasal Spray
  • Kurve Technologies Introduces Blog on Nasal Drug Delivery
  • Accentia Extends Agreement with Mayo Foundation
  • Nastech Signs Development and License Agreement with Amylin
  • MedImmune's FluMist Plant Gets FDA Approval
  • ShinNippon Subsidiaries Sign Licensing Agreement with Tokai Pharmaceuticals
  • MeadWestvaco Acquires Saint-Gobain Calmar
  • Merck Terminates PYY3-36 Partnership with Nastech
  • Inspire Signs Licensing Agreement with Boehringer Ingelheim
  • P&G Partners with Nastech to Develop PTH(1-34)
  • Unigene Laboratories Signs Distribution Agreement with Tzamal Bio Pharma
  • GlaxoSmithKline Seeks Marketing Approval for Fluticasone Furoate in the US and Europe
  • Kurve Technology Relocates Corporate Headquarters
  • Kurve Inks an Agreement with DARA BioSciences
  • Kurve Enters into a Development Agreement with Schering-Plough
  • Altana Submits NDS for Approval of Ciclesonide Nasal Spray in Canada
  • Altana Pharma AG Receives FDA Approval for Pediatric Use of Omnaris
  • Intranasal Therapeutics Inc. Receives Financial Funding
  • FDA Completes Pre-Approval Inspections at Nastech's Washington Facility
  • Kos Signs Exclusive License Agreement with SkyePharma
  • Bentley Signs Agreement with Biocon
  • Intranasal Therapeutics Files Patent Application for Synthetic THC
  • Ionix Pharmaceuticals in Collaboration with Reckitt Benckiser for Drug Development
  • University of Kentucky Receives Patent for new Intranasal Device
  • Intranasal Technology Extends Collaboration with Aegis Therapeutics
  • Accentia Biopharmaceuticals Signs License Agreement with Collegium Pharmaceuticals
  • Aegis Therapeutics Extends License Agreement with Intranasal Technologies
  • Bentley Pharmaceuticals Signs Agreement with Dong Sung Pharmaceuticals
  • Unigene Gets FDA Approval for Fortical Calcitonin- Salmon Nasal Spray
  • OptiNose Signs Collaborative Agreement with MedPharm
  • West Pharmaceutical Divests Drug Delivery Business to Archimedes Pharma
  • Nastech Pharmaceutical Receives FDA Approval for Nascobal Nasal Spray

11. FOCUS ON SELECT GLOBAL PLAYERS

  • Aegis Therapeutics LLC (USA)
  • Alza Corporation (USA)
  • AptarGroup, Inc. (USA)
  • Archimedes Pharma Limited. (UK)
  • AstraZeneca Plc. (UK)
  • MedImmune, Inc. (USA)
  • Bayer Consumer Care (USA)
  • Bespak Plc. (UK)
  • GlaxoSmithKline Plc. (UK)
  • Ikano Therapeutics Inc. (USA)
  • Javelin Pharmaceuticals, Inc. (USA)
  • Kurve Technology, Inc. (USA)
  • Marina Biotech, Inc. (USA)
  • Merck & Co., Inc. (USA)
  • Novartis AG (Switzerland)
  • OptiNose AS (Norway)
  • Pfizer, Inc. (USA)
  • Rexam Plc. (UK)
  • Sanofi S.A. (France)
  • Unigene Laboratories, Inc. (USA)

12. MARKET ANALYTICS

    • Table 7: The US Recent Past, Current & Future Analysis for Intranasal Drug Delivery by Therapeutic Area - Allergic Infections, Analgesics, Osteoporosis, and Vaccinations Markets Independently Analyzed by Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 8: The US Historic Review for Intranasal Drug Delivery by Therapeutic Area - Allergic Infections, Analgesics, Osteoporosis, and Vaccinations Markets Independently Analyzed by Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
    • Table 9: The US 15-Year Perspective for Intranasal Drug Delivery by Therapeutic Area -Percentage Breakdown of Values Sales for Allergic Infections, Analgesics, Osteoporosis, and Vaccinations for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)

III. COMPETITIVE LANDSCAPE

Back to Top